Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model

Nobuyuki Tanaka, Ryuichi Mizuno, Yota Yasumizu, Keiichi Ito, Suguru Shirotake, Ayako Masunaga, Yujiro Ito, Yasumasa Miyazaki, Masayuki Hagiwara, Kent Kanao, Shuji Mikami, Ken Nakagawa, Tetsuo Momma, Takeshi Masuda, Tomohiko Asano, Masafumi Oyama, Mototsugu Oya

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk model has been designed for prognostification in patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy. One factor is neutrophil count; however, increasing evidence has suggested the superiority of neutrophil-to-lymphocyte ratio (NLR) for predicting outcome. In this study, we evaluate the prognostic effect of NLR levels on patients with mRCC treated with targeted therapy, and then we compare the predictive accuracy of the IMDC risk model and its modified one by using NLR, instead of neutrophil count. Patients and method A total of 277 patients are included for the analysis. All patients underwent targeted therapies and associated outcome are assessed using multivariate analysis. Results Pretreatment NLR levels are elevated in 30.3% and 23.1% of patients in the first-line and subsequent second-line setting, respectively. Kaplan-Meier curves reveal that elevated pretreatment NLR is significantly associated with poor overall survival (OS) since first-line (P<0.001) and second-line targeted therapy administration (P<0.001). Also, multivariate analyses show that elevated pretreatment NLR is an independent predictor for poor OS since first-line and second-line targeted therapy administration. The addition of NLR to the IMDC risk model, instead of neutrophil count, significantly improves the predictive accuracy for OS, and estimated gain is 1.7% and 6.2% in first-line and second-line targeted therapy, respectively. Conclusion Changes in NLR levels could be predictive for prognosis in patients with mRCC treated with first-line and second-line targeted therapy. The addition of NLR significantly improves the predictive accuracy of the IMDC risk model in the first-line and subsequent second-line setting.

Original languageEnglish
Pages (from-to)39.e19-39.e28
JournalUrologic Oncology: Seminars and Original Investigations
Volume35
Issue number2
DOIs
Publication statusPublished - 2017 Feb 1

Fingerprint

Renal Cell Carcinoma
Neutrophils
Lymphocytes
Therapeutics
Survival
Multivariate Analysis
Databases

Keywords

  • Metastasis
  • Neutrophil
  • NLR
  • Outcome
  • Prognosis
  • Renal cell carcinoma
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy : A proposal of the modified-IMDC risk model. / Tanaka, Nobuyuki; Mizuno, Ryuichi; Yasumizu, Yota; Ito, Keiichi; Shirotake, Suguru; Masunaga, Ayako; Ito, Yujiro; Miyazaki, Yasumasa; Hagiwara, Masayuki; Kanao, Kent; Mikami, Shuji; Nakagawa, Ken; Momma, Tetsuo; Masuda, Takeshi; Asano, Tomohiko; Oyama, Masafumi; Oya, Mototsugu.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 35, No. 2, 01.02.2017, p. 39.e19-39.e28.

Research output: Contribution to journalArticle

Tanaka, Nobuyuki ; Mizuno, Ryuichi ; Yasumizu, Yota ; Ito, Keiichi ; Shirotake, Suguru ; Masunaga, Ayako ; Ito, Yujiro ; Miyazaki, Yasumasa ; Hagiwara, Masayuki ; Kanao, Kent ; Mikami, Shuji ; Nakagawa, Ken ; Momma, Tetsuo ; Masuda, Takeshi ; Asano, Tomohiko ; Oyama, Masafumi ; Oya, Mototsugu. / Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy : A proposal of the modified-IMDC risk model. In: Urologic Oncology: Seminars and Original Investigations. 2017 ; Vol. 35, No. 2. pp. 39.e19-39.e28.
@article{c30e1d60c1734902b391375eca796586,
title = "Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model",
abstract = "Purpose The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk model has been designed for prognostification in patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy. One factor is neutrophil count; however, increasing evidence has suggested the superiority of neutrophil-to-lymphocyte ratio (NLR) for predicting outcome. In this study, we evaluate the prognostic effect of NLR levels on patients with mRCC treated with targeted therapy, and then we compare the predictive accuracy of the IMDC risk model and its modified one by using NLR, instead of neutrophil count. Patients and method A total of 277 patients are included for the analysis. All patients underwent targeted therapies and associated outcome are assessed using multivariate analysis. Results Pretreatment NLR levels are elevated in 30.3{\%} and 23.1{\%} of patients in the first-line and subsequent second-line setting, respectively. Kaplan-Meier curves reveal that elevated pretreatment NLR is significantly associated with poor overall survival (OS) since first-line (P<0.001) and second-line targeted therapy administration (P<0.001). Also, multivariate analyses show that elevated pretreatment NLR is an independent predictor for poor OS since first-line and second-line targeted therapy administration. The addition of NLR to the IMDC risk model, instead of neutrophil count, significantly improves the predictive accuracy for OS, and estimated gain is 1.7{\%} and 6.2{\%} in first-line and second-line targeted therapy, respectively. Conclusion Changes in NLR levels could be predictive for prognosis in patients with mRCC treated with first-line and second-line targeted therapy. The addition of NLR significantly improves the predictive accuracy of the IMDC risk model in the first-line and subsequent second-line setting.",
keywords = "Metastasis, Neutrophil, NLR, Outcome, Prognosis, Renal cell carcinoma, Targeted therapy",
author = "Nobuyuki Tanaka and Ryuichi Mizuno and Yota Yasumizu and Keiichi Ito and Suguru Shirotake and Ayako Masunaga and Yujiro Ito and Yasumasa Miyazaki and Masayuki Hagiwara and Kent Kanao and Shuji Mikami and Ken Nakagawa and Tetsuo Momma and Takeshi Masuda and Tomohiko Asano and Masafumi Oyama and Mototsugu Oya",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.urolonc.2016.10.001",
language = "English",
volume = "35",
pages = "39.e19--39.e28",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy

T2 - A proposal of the modified-IMDC risk model

AU - Tanaka, Nobuyuki

AU - Mizuno, Ryuichi

AU - Yasumizu, Yota

AU - Ito, Keiichi

AU - Shirotake, Suguru

AU - Masunaga, Ayako

AU - Ito, Yujiro

AU - Miyazaki, Yasumasa

AU - Hagiwara, Masayuki

AU - Kanao, Kent

AU - Mikami, Shuji

AU - Nakagawa, Ken

AU - Momma, Tetsuo

AU - Masuda, Takeshi

AU - Asano, Tomohiko

AU - Oyama, Masafumi

AU - Oya, Mototsugu

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Purpose The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk model has been designed for prognostification in patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy. One factor is neutrophil count; however, increasing evidence has suggested the superiority of neutrophil-to-lymphocyte ratio (NLR) for predicting outcome. In this study, we evaluate the prognostic effect of NLR levels on patients with mRCC treated with targeted therapy, and then we compare the predictive accuracy of the IMDC risk model and its modified one by using NLR, instead of neutrophil count. Patients and method A total of 277 patients are included for the analysis. All patients underwent targeted therapies and associated outcome are assessed using multivariate analysis. Results Pretreatment NLR levels are elevated in 30.3% and 23.1% of patients in the first-line and subsequent second-line setting, respectively. Kaplan-Meier curves reveal that elevated pretreatment NLR is significantly associated with poor overall survival (OS) since first-line (P<0.001) and second-line targeted therapy administration (P<0.001). Also, multivariate analyses show that elevated pretreatment NLR is an independent predictor for poor OS since first-line and second-line targeted therapy administration. The addition of NLR to the IMDC risk model, instead of neutrophil count, significantly improves the predictive accuracy for OS, and estimated gain is 1.7% and 6.2% in first-line and second-line targeted therapy, respectively. Conclusion Changes in NLR levels could be predictive for prognosis in patients with mRCC treated with first-line and second-line targeted therapy. The addition of NLR significantly improves the predictive accuracy of the IMDC risk model in the first-line and subsequent second-line setting.

AB - Purpose The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk model has been designed for prognostification in patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy. One factor is neutrophil count; however, increasing evidence has suggested the superiority of neutrophil-to-lymphocyte ratio (NLR) for predicting outcome. In this study, we evaluate the prognostic effect of NLR levels on patients with mRCC treated with targeted therapy, and then we compare the predictive accuracy of the IMDC risk model and its modified one by using NLR, instead of neutrophil count. Patients and method A total of 277 patients are included for the analysis. All patients underwent targeted therapies and associated outcome are assessed using multivariate analysis. Results Pretreatment NLR levels are elevated in 30.3% and 23.1% of patients in the first-line and subsequent second-line setting, respectively. Kaplan-Meier curves reveal that elevated pretreatment NLR is significantly associated with poor overall survival (OS) since first-line (P<0.001) and second-line targeted therapy administration (P<0.001). Also, multivariate analyses show that elevated pretreatment NLR is an independent predictor for poor OS since first-line and second-line targeted therapy administration. The addition of NLR to the IMDC risk model, instead of neutrophil count, significantly improves the predictive accuracy for OS, and estimated gain is 1.7% and 6.2% in first-line and second-line targeted therapy, respectively. Conclusion Changes in NLR levels could be predictive for prognosis in patients with mRCC treated with first-line and second-line targeted therapy. The addition of NLR significantly improves the predictive accuracy of the IMDC risk model in the first-line and subsequent second-line setting.

KW - Metastasis

KW - Neutrophil

KW - NLR

KW - Outcome

KW - Prognosis

KW - Renal cell carcinoma

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85006097314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006097314&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2016.10.001

DO - 10.1016/j.urolonc.2016.10.001

M3 - Article

C2 - 27825515

AN - SCOPUS:85006097314

VL - 35

SP - 39.e19-39.e28

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 2

ER -